Related Experiment Video
Updated: Apr 8, 2026
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes
Anne-Joy M de Graan1, Alex Sparreboom1,2, Peter de Bruijn1
1Department of Medical Oncology, Erasmus MC Cancer Institute, 's-Gravendijkwal 230, 3015CE, Rotterdam.
Aim:
Taxanes are anti-cancer agents used to treat several types of solid tumours. They are metabolized by cytochrome P450 (CYP) 3A, displaying a large pharmacokinetic (PK) variability. In this study, we evaluated the endogenous CYP3A4 marker 4β-hydroxycholesterol (4β-OHC) as a potential individual taxane PK predictor.
Methods:
Serum 4β-OHC and cholesterol concentrations were determined in 291 paclitaxel and 151 docetaxel-treated patients, and were subsequently correlated with taxane clearance.
Results:
In the patients treated with paclitaxel, no clinically relevant correlations between the 4β-OHC or 4β-OHC : cholesterol ratio and paclitaxel clearance were found. In the patients treated with docetaxel, 4β-OHC concentration was weakly correlated with docetaxel clearance in males (r = 0.35 P = 0.01, 95% CI 0.08, 0.58). Of the 10% patients with taxane outlier clearance values, 4β-OHC did correlate with docetaxel clearance in males (r = 0.76, P = 0.03, 95% CI 0.12, 0.95).
Conclusion:
There was no clinical correlation between paclitaxel clearance and the CYP3A4 activity markers 4β-OHC or the 4β-OHC : cholesterol ratio. A weak correlation was observed between 4β-OHC and docetaxel clearance, but only in males. This endogenous CYP3A4 marker has limited predictive value for taxane clearance in patients.
Insights
The endogenous marker 4β-hydroxycholesterol (4β-OHC) showed limited predictive value for taxane pharmacokinetic variability. No correlation was found for paclitaxel, and only a weak correlation for docetaxel in males.
Area of Science:
- Pharmacology
- Oncology
- Biochemistry
Background:
- Taxanes are crucial anti-cancer drugs for solid tumors.
- Cytochrome P450 3A (CYP3A) enzymes metabolize taxanes, leading to significant pharmacokinetic variability.
- Predicting individual taxane pharmacokinetics is essential for optimizing treatment efficacy and minimizing toxicity.
Purpose of the Study:
- To evaluate 4β-hydroxycholesterol (4β-OHC), an endogenous marker of CYP3A4 activity, as a predictor of individual taxane pharmacokinetic variability.
- To assess the correlation between 4β-OHC and cholesterol levels with the clearance of paclitaxel and docetaxel.
Main Methods:
- Serum concentrations of 4β-OHC and cholesterol were measured in 291 paclitaxel-treated and 151 docetaxel-treated patients.
- These biomarker levels were correlated with the measured taxane clearance rates.
Main Results:
- No clinically significant correlation was observed between 4β-OHC or the 4β-OHC:cholesterol ratio and paclitaxel clearance.
- A weak correlation was found between 4β-OHC and docetaxel clearance in male patients (r = 0.35, P = 0.01).
- In male patients with outlier docetaxel clearance values (top 10%), a stronger correlation with 4β-OHC was observed (r = 0.76, P = 0.03).
Conclusions:
- The endogenous CYP3A4 activity marker 4β-OHC has limited predictive value for taxane clearance.
- Clinical correlation between 4β-OHC and paclitaxel clearance was not established.
- A weak, sex-specific correlation was noted for docetaxel clearance, suggesting limited utility in routine clinical practice for predicting taxane pharmacokinetics.
More Related Videos
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
